Wegovy's active chemical: semaglutide explained

Step 1, Where semaglutide comes from and what makes it different from the natural hormone

Your small intestine releases a peptide hormone called GLP-1 (glucagon-like peptide-1) in response to food. The problem with natural GLP-1 is that it breaks down within minutes. Semaglutide is a chemically modified version of that hormone, engineered to resist the enzyme (dipeptidyl peptidase-4) that normally degrades it so quickly.

The key structural change is a fatty-acid side chain attached to the peptide backbone. That chain allows semaglutide to bind loosely to albumin, a protein in the bloodstream, which shields the molecule from degradation. The result is a half-life of roughly seven days, the reason a once-weekly injection is enough to maintain a steady level in the body. For a deeper look at the molecular architecture, our page on the semaglutide chemical structure walks through the exact peptide sequence and what each modification does.

The semaglutide overview on our site covers how this chemistry translates into practical weight management, including how long it takes for the medicine to reach a stable concentration after starting treatment.

Step 2, What semaglutide does once it reaches its receptors

GLP-1 receptors sit in several places: the hypothalamus (the brain's appetite-regulation hub), the pancreas, the stomach lining and the heart. When semaglutide binds to hypothalamic receptors it reduces hunger signals; most people find they feel full on less food and think about eating less often. In the stomach it slows gastric emptying, which extends the feeling of fullness after meals and moderates the blood-sugar spike that follows eating.

In the pancreas it stimulates insulin release in a glucose-dependent way (that is, only when blood sugar is elevated) and suppresses glucagon, the hormone that raises blood sugar. This dual effect is why semaglutide was developed first as a diabetes treatment and later adapted at a higher dose (2.4 mg weekly) for weight management under the brand name Wegovy.

The full Wegovy guide on this site covers how those receptor effects play out over the titration schedule and what to expect at each stage of treatment.

Step 3, What the clinical trial evidence shows about this chemical in practice

The STEP 1 trial, published in the New England Journal of Medicine, randomised adults with obesity (without diabetes) to 2.4 mg semaglutide weekly or placebo, over 68 weeks alongside lifestyle support. Average weight reduction in the semaglutide group was around 15%. That figure comes directly from the chemical's mechanism: sustained GLP-1 receptor activation, week after week, shifting the appetite set-point downward. The semaglutide research timeline page traces how the molecule moved from early compound screening to these large phase-3 outcomes.

A higher 7.2 mg maintenance dose of Wegovy was approved by the MHRA in early 2026, with trial data reporting roughly 20.7% average weight loss over 72 weeks, approaching the results seen with tirzepatide at the highest dose. The Wegovy pricing page explains what private treatment typically costs in the UK once the medicine has been prescribed. NICE's appraisal of semaglutide for weight management (TA875) describes the clinical framework within which NHS prescribing operates, including the specialist-service requirement.

Step 4 (Practical points that follow from the chemistry

Because semaglutide has a week-long half-life, missing a single dose has less immediate impact than missing a daily medicine) but it is not harmless to skip one regularly. The prescriber and Patient Information Leaflet should guide any missed-dose decisions; this is not something to improvise.

The fatty-acid side chain that extends semaglutide's half-life also affects how it interacts with other oral medicines. For women on oral contraceptives taking tirzepatide (a separate GLP-1 medicine), there is clear guidance to add a barrier method; the evidence is less definitive for semaglutide, but this is still worth discussing with your prescriber before starting. Our page on semaglutide and steroids covers interaction questions in more detail.

The NHS provides patient-level information about semaglutide's side-effect profile on its semaglutide medicines page. GI effects (nausea, loose stools, indigestion) are the most commonly reported, typically peaking in the first few weeks after a dose increase then settling. Most people find taking the weekly injection on the same morning each week, before the kettle goes on, builds the habit quickly.

If you'd like a prescriber to assess whether Wegovy is clinically right for you, you can start a free consultation with our GPhC-registered team. The semaglutide chemical formula page has further detail on the molecule's exact composition for those who want the technical specifics, and our clinical team page outlines the prescriber oversight behind every nume consultation at nume.